Published in Medical Devices and Surgical Technology Week, July 17th, 2005
The acquisition is expected to close in McKesson's second fiscal quarter ending September 30, 2005, subject to customary conditions including regulatory review. The sale of McKesson BioServices, which is subject to certain post-closing adjustments, is anticipated to result in an after-tax gain of approximately $13 million to $15 million in the quarter in which the transaction closes. McKesson will report BioServices financial results as a discontinued operation in its first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.